Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

被引：3

作者：

Muranen, Taru A. ^{[1
]}

Khan, Sofia ^{[1
,2
,3
]}

Fagerholm, Rainer ^{[1
]}

Aittomaeki, Kristiina ^{[4
]}

Cunningham, Julie M. ^{[5
]}

Dennis, Joe ^{[6
]}

Leslie, Goska ^{[6
]}

McGuffog, Lesley ^{[6
]}

Parsons, Michael T. ^{[7
]}

Simard, Jacques ^{[8
]}

Slager, Susan ^{[9
]}

Soucy, Penny ^{[8
]}

Easton, Douglas F. ^{[6
,10
]}

Tischkowitz, Marc ^{[11
,12
,13
]}

Spurdle, Amanda B. ^{[7
]}

Schmutzler, Rita K. ^{[14
,15
,16
,17
]}

Wappenschmidt, Barbara ^{[14
,15
,16
,17
]}

Hahnen, Eric ^{[14
,15
,16
,17
]}

Hooning, Maartje J. ^{[18
]}

Singer, Christian F. ^{[19
]}

Wagner, Gabriel ^{[19
]}

Thomassen, Mads ^{[20
]}

Pedersen, Inge Sokilde ^{[21
,22
]}

Domchek, Susan M. ^{[23
]}

Nathanson, Katherine L. ^{[23
]}

Lazaro, Conxi ^{[24
]}

Rossing, Caroline Maria ^{[25
]}

Andrulis, Irene L. ^{[26
,27
]}

Teixeira, Manuel R. ^{[28
,29
]}

James, Paul ^{[30
,31
]}

Garber, Judy ^{[32
]}

Weitzel, Jeffrey N. ^{[33
]}

Jakubowska, Anna ^{[34
,35
]}

Yannoukakos, Drakoulis ^{[36
]}

John, Esther M. ^{[37
]}

Southey, Melissa C. ^{[38
,39
]}

Schmidt, Marjanka K. ^{[40
,41
]}

Antoniou, Antonis C. ^{[6
]}

Chenevix-Trench, Georgia ^{[7
]}

Blomqvist, Carl ^{[42
,43
]}

Nevanlinna, Heli ^{[1
]}

机构：

[1] Univ Helsinki, Helsinki Univ Hosp, Dept Obstet & Gynecol, Helsinki, Finland

[2] Univ Turku, Turku, Finland

[3] Abo Akad Univ, Turku Biosci Ctr, Turku, Finland

[4] Univ Helsinki, Dept Clin Genet, Helsinki Univ Hosp, Helsinki, Finland

[5] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA

[6] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England

[7] QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Brisbane, Qld, Australia

[8] CHU Quebec Res Ctr, Genom Ctr, Quebec City, PQ, Canada

[9] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA

[10] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Oncol, Cambridge, England

[11] McGill Univ, Program Canc Genet, Dept Human Genet, Montreal, PQ, Canada

[12] McGill Univ, Program Canc Genet, Dept Oncol, Montreal, PQ, Canada

[13] Univ Cambridge, Dept Med Genet, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England

[14] Univ Cologne, Ctr Hereditary Breast & Ovarian Canc, Fac Med, Cologne, Germany

[15] Univ Cologne, Ctr Hereditary Breast & Ovarian Canc, Univ Hosp Cologne, Cologne, Germany

[16] Univ Cologne, Ctr Mol Med Cologne CMMC, Fac Med, Cologne, Germany

[17] Univ Cologne, Ctr Mol Med Cologne CMMC, Univ Hosp Cologne, Cologne, Germany

[18] Erasmus MC Canc Inst, Dept Med Oncol, Family Canc Clin, Rotterdam, Netherlands

[19] Med Univ Vienna, Dept OB GYN & Comprehens Canc Ctr, Vienna, Austria

[20] Odense Univ Hosp, Dept Clin Genet, Odence C, Denmark

[21] Aalborg Univ Hosp, Mol Diagnost, Aalborg, Denmark

[22] Aalborg Univ, Dept Clin Med, Aalborg, Denmark

[23] Univ Penn, Dept Med, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA

[24] CIBERONC, Mol Diagnost Unit, Hereditary Canc Program, ICOI DIBELL Bellvitge Biomed Res Inst,Catalan Ins, Barcelona, Spain

[25] Copenhagen Univ Hosp, Rigshosp, Ctr Genom Med, Copenhagen, Denmark

[26] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Fred A Litwin Ctr Canc Genet, Toronto, ON, Canada

[27] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada

[28] Portuguese Oncol Inst, Dept Genet, Porto, Portugal

[29] Univ Porto, Biomed Sci Inst ICBAS, Porto, Portugal

[30] Parkville Familial Canc Ctr, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[31] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[32] Dana Farber Canc Inst, Canc Risk & Prevent Clin, Boston, MA 02115 USA

[33] City Hope Natl Med Ctr, Clin Canc Gen, Duarte, CA USA

[34] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland

[35] Pomeranian Med Univ, Independent Lab Mol Biol & Genet Diagnost, Szczecin, Poland

[36] INRASTES, Mol Diagnost Lab, Natl Ctr Sci Res Demokritos, Athens, Greece

[37] Stanford Univ, Stanford Canc Inst, Sch Med, Dept Med,Div Oncol, Stanford, CA 94305 USA

[38] Monash Univ, Precis Med, Sch Clin Sci, Monash Hlth, Clayton, Vic, Australia

[39] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic, Australia

[40] Netherlands Canc Inst Antoni van Leeuwenhoek Hosp, Div Mol Pathol, Amsterdam, Netherlands

[41] Netherlands Canc Inst Antoni van Leeuwenhoek Hosp, Div Psychosocial Res & Epidemiol, Amsterdam, Netherlands

[42] Univ Helsinki, Dept Oncol, Helsinki Univ Hosp, Helsinki, Finland

[43] Orebro Univ Hosp, Dept Oncol, Orebro, Sweden

来源：

NPJ BREAST CANCER | 2020年 / 6卷 / 01期

基金：

英国医学研究理事会; 美国国家卫生研究院; 加拿大健康研究院;

关键词：

INTERNATIONAL EXPERT CONSENSUS; FALSE DISCOVERY; PRIMARY THERAPY; CELLS; EXPRESSION; REVEALS; OVARIAN; GENES; RISK; IDENTIFICATION;

D O I：

10.1038/s41523-020-00185-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients, the carriers of germline pathogenic variants in BRCA1 or BRCA2 genes. We found that rs57025206 was significantly associated with the overall survival, predicting higher mortality of BRCA1 carrier patients with estrogen receptor-negative breast cancer, with a hazard ratio 4.37 (95% confidence interval 3.03-6.30, P=3.1x10(-9)). Multivariable analysis adjusted for tumor characteristics suggested that rs57025206 was an independent survival marker. In addition, our exploratory analyses suggest that the associations between genetic variants and breast cancer patient survival may depend on tumor biological subgroup and clinical patient characteristics.

引用

页数：13

共 50 条

[1] Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer
Taru A. Muranen
Sofia Khan
Rainer Fagerholm
Kristiina Aittomäki
Julie M. Cunningham
Joe Dennis
Goska Leslie
Lesley McGuffog
Michael T. Parsons
Jacques Simard
Susan Slager
Penny Soucy
Douglas F. Easton
Marc Tischkowitz
Amanda B. Spurdle
Rita K. Schmutzler
Barbara Wappenschmidt
Eric Hahnen
Maartje J. Hooning
Christian F. Singer
Gabriel Wagner
Mads Thomassen
Inge Sokilde Pedersen
Susan M. Domchek
Katherine L. Nathanson
Conxi Lazaro
Caroline Maria Rossing
Irene L. Andrulis
Manuel R. Teixeira
Paul James
Judy Garber
Jeffrey N. Weitzel
Anna Jakubowska
Drakoulis Yannoukakos
Esther M. John
Melissa C. Southey
Marjanka K. Schmidt
Antonis C. Antoniou
Georgia Chenevix-Trench
Carl Blomqvist
Heli Nevanlinna
npj Breast Cancer, 6
[2] Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer
Corso, Giovanni
Girardi, Antonia
Calvello, Mariarosaria
Gandini, Sara
Gaeta, Aurora
Marabelli, Monica
Magnoni, Francesca
Veronesi, Paolo
Guerrieri-Gonzaga, Aliana
Bonanni, Bernardo
BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (01) : 103 - 112
[3] Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer
Giovanni Corso
Antonia Girardi
Mariarosaria Calvello
Sara Gandini
Aurora Gaeta
Monica Marabelli
Francesca Magnoni
Paolo Veronesi
Aliana Guerrieri-Gonzaga
Bernardo Bonanni
Breast Cancer Research and Treatment, 2023, 197 : 103 - 112
[4] Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants
Zhang, Zhenzhen
Ye, Shangyuan
Bernhardt, Sarah M.
Nelson, Heidi D.
Velie, Ellen M.
Borges, Virginia F.
Woodward, Emma R.
Evans, D. Gareth R.
Schedin, Pepper J.
JAMA NETWORK OPEN, 2024, 7 (04) : E247421
[5] Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants
Yao, Lu
Sun, Jie
Hu, Li
Chen, Jiuan
Zhang, Juan
Xu, Ye
Xie, Yuntao
JOURNAL OF HUMAN GENETICS, 2022, 67 (11) : 639 - 642
[6] Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants
Lu Yao
Jie Sun
Li Hu
Jiuan Chen
Juan Zhang
Ye Xu
Yuntao Xie
Journal of Human Genetics, 2022, 67 : 639 - 642
[7] Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
Edaily, Sarah
Abdel-Razeq, Hikmat
ONCOTARGETS AND THERAPY, 2022, 15 : 815 - 826
[8] Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2
Phillips, Kelly-Anne
Kotsopoulos, Joanne
Domchek, Susan
Chamberlain, James
Bassett, Julie
Aeilts, Amber
Andrulis, Irene
Buys, Saundra
Cui, Wanda
Daly, Mary
Eisen, Andrea
Foulkes, William
Friedlander, Michael
Gronwald, Jacek
Hopper, John
John, Esther
Karlan, Beth
Kim, Raymond
Lubinski, Jan
Metcalfe, Kelly
Nathanson, Katherine
Singer, Christian F.
Symecko, Heather
Tung, Nadine
Narod, Steven
Terry, Mary Beth
Milne, Roger
CANCER RESEARCH, 2024, 84 (09)
[9] Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer
Foulkes, William D.
Polak, Paz
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024,
[10] The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women
Larionov, Alexey
Fewings, Eleanor
Redman, James
Goldgraben, Mae
Clark, Graeme
Boice, John
Concannon, Patrick
Bernstein, Jonine
Conti, David V.
WECARE Study Collaborative Grp, Marc
Tischkowitz, Marc
CANCERS, 2023, 15 (02)

← 1 2 3 4 5 →